(-0.04%) 5 476.50 points
(-0.07%) 38 791 points
(-0.01%) 19 920 points
(0.34%) $80.60
(1.26%) $2.82
(0.24%) $2 334.60
(-0.16%) $29.35
(-0.19%) $969.10
(0.01%) $0.932
(-0.16%) $10.64
(0.05%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States...
Stats | |
---|---|
Šios dienos apimtis | 445 642 |
Vidutinė apimtis | 208 447 |
Rinkos kapitalizacija | 69.10M |
EPS | $-0.240 ( Q1 | 2024-05-15 ) |
Kita pelno data | ( $-0.350 ) 2024-08-08 |
Last Dividend | $0.0150 ( 2015-09-16 ) |
Next Dividend | $0 ( N/A ) |
P/E |
2.91 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00500 (0.39%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-29 | Deshpande Milind | Buy | 20 000 | Common Stock |
2024-05-29 | Jackson Scott Thomas | Buy | 20 000 | Common Stock |
2024-05-29 | Mahadevia Ankit | Buy | 20 000 | Common Stock |
2024-05-29 | Vink Patrick V.j.j. | Buy | 20 000 | Common Stock |
2024-05-29 | Tregoning Kathleen | Buy | 20 000 | Common Stock |
INSIDER POWER |
---|
65.38 |
Last 96 transactions |
Buy: 6 082 184 | Sell: 2 240 393 |
Tūris Koreliacija
Spero Therapeutics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
ALRM | 0.808 |
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Spero Therapeutics Inc Koreliacija - Valiuta/Žaliavos
Spero Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $96.74M |
Bruto pelnas: | $96.37M (99.62 %) |
EPS: | $0.430 |
FY | 2023 |
Pajamos: | $96.74M |
Bruto pelnas: | $96.37M (99.62 %) |
EPS: | $0.430 |
FY | 2022 |
Pajamos: | $48.58M |
Bruto pelnas: | $47.03M (96.82 %) |
EPS: | $-1.280 |
FY | 2021 |
Pajamos: | $18.26M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-2.91 |
Financial Reports:
No articles found.
Spero Therapeutics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0100 | 2010-03-30 |
Last Dividend | $0.0150 | 2015-09-16 |
Next Dividend | $0 | N/A |
Payout Date | 2015-10-07 | |
Next Payout Date | N/A | |
# dividends | 23 | -- |
Total Paid Out | $0.285 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.07 | -- |
Div. Sustainability Score | 8.12 | |
Div.Growth Potential Score | 0.834 | |
Div. Directional Score | 4.48 | -- |
Year | Amount | Yield |
---|---|---|
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
16 Sep 2015 | $0.0150 | 07 Aug 2015 | 18 Sep 2015 | 07 Oct 2015 |
17 Jun 2015 | $0.0150 | 08 May 2015 | 19 Jun 2015 | 07 Jul 2015 |
18 Mar 2015 | $0.0150 | 09 Mar 2015 | 20 Mar 2015 | 07 Apr 2015 |
17 Dec 2014 | $0.0150 | 05 Nov 2014 | 19 Dec 2014 | 06 Jan 2015 |
17 Sep 2014 | $0.0150 | 08 Aug 2014 | 19 Sep 2014 | 07 Oct 2014 |
18 Jun 2014 | $0.0150 | 08 May 2014 | 20 Jun 2014 | 07 Jul 2014 |
19 Mar 2014 | $0.0150 | 10 Mar 2014 | 21 Mar 2014 | 07 Apr 2014 |
17 Dec 2013 | $0.0150 | 08 Nov 2013 | 19 Dec 2013 | 06 Jan 2014 |
17 Sep 2013 | $0.0150 | 07 Aug 2013 | 19 Sep 2013 | 07 Oct 2013 |
12 Jun 2013 | $0.0150 | 08 May 2013 | 14 Jun 2013 | 05 Jul 2013 |
20 Mar 2013 | $0.0150 | 08 Mar 2013 | 22 Mar 2013 | 05 Apr 2013 |
17 Dec 2012 | $0.0100 | 07 Nov 2012 | 30 Nov -0001 | 07 Jan 2013 |
17 Sep 2012 | $0.0100 | 08 Aug 2012 | 30 Nov -0001 | 05 Oct 2012 |
13 Jun 2012 | $0.0100 | 10 May 2012 | 30 Nov -0001 | 06 Jul 2012 |
20 Mar 2012 | $0.0100 | 12 Mar 2012 | 30 Nov -0001 | 04 Apr 2012 |
12 Dec 2011 | $0.0100 | 09 Nov 2011 | 30 Nov -0001 | 05 Jan 2012 |
14 Sep 2011 | $0.0100 | 10 Aug 2011 | 30 Nov -0001 | 05 Oct 2011 |
13 Jun 2011 | $0.0100 | 11 May 2011 | 30 Nov -0001 | 08 Jul 2011 |
22 Mar 2011 | $0.0100 | 11 Mar 2011 | 30 Nov -0001 | 04 Apr 2011 |
13 Dec 2010 | $0.0100 | 10 Nov 2010 | 30 Nov -0001 | 31 Dec 2010 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.229 | 1.500 | 5.42 | 8.14 | [0 - 0.5] |
returnOnAssetsTTM | 0.140 | 1.200 | 5.35 | 6.42 | [0 - 0.3] |
returnOnEquityTTM | 0.300 | 1.500 | 7.77 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.35 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.26 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.967 | 1.500 | 0.182 | 0.273 | [0.2 - 2] |
debtRatioTTM | 0.0313 | -1.500 | 9.48 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 15.57 | 1.000 | 5.34 | 5.34 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.265 | 2.00 | -0.0885 | -0.177 | [0 - 30] |
freeCashFlowPerShareTTM | -0.265 | 2.00 | -0.133 | -0.265 | [0 - 20] |
debtEquityRatioTTM | 0.0545 | -1.500 | 9.78 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.955 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.146 | 1.000 | 9.07 | 9.07 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -2.71 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.610 | 0.800 | 9.27 | 7.41 | [0.5 - 2] |
Total Score | 8.12 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 3.40 | 1.000 | 9.76 | 0 | [1 - 100] |
returnOnEquityTTM | 0.300 | 2.50 | 8.57 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.265 | 2.00 | -0.0885 | -0.265 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.265 | 2.00 | -0.0885 | -0.177 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.00939 | 1.500 | -3.40 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.139 | 1.000 | -5.97 | 0 | [0.1 - 0.5] |
Total Score | 0.834 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.